ArticleJournal of assisted reproduction and genetics2026
A retrospective case-control study of in vitro fertilization in patients with BRCA1/2 mutation.
Article in Journal of assisted reproduction and genetics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
To evaluate IVF outcomes with pre-implantation genetic testing for monogenic disorders (PGT-M) for patients with BRCA1/2 mutations compared to patients utilizing PGT for other reasons. This retrospective case-control study compared patients undergoing IVF/PGT-M for BRCA1/2 mutations to control cohorts, either undergoing IVF for male/tubal infertility with elective PGT-A or PGT-M for other genetic conditions. The primary outcome was time to first live birth, indexed by IVF cycle number and analyzed using time-to-event methods with right censoring. Secondary outcomes included embryology yield, number of IVF cycles required to achieve live birth among those who succeeded, and live birth per initiated IVF cycle. Among 195 patients (45 BRCA1/2 PGT-M, 60 non-BRCA PGT-M, and 90 PGT-A), number of oocytes retrieved, blastocyst yield, and embryo maturation did not differ significantly across cohorts. BRCA carriers required more cycles to achieve live birth compared with the PGT-A cohort, but comparable cycles compared to non-BRCA PGT-M patients. Time-to-event analyses demonstrated no significant difference in time to live birth across cohorts (log-rank P = 0.71). Patients undergoing PGT-M, including BRCA carriers, experience greater cumulative IVF cycle burden. However, the per cycle and per transfer probability of achieving a live birth was similar across indications, supporting reassuring counseling for BRCA carriers pursing IVF/PGT-M.
Indexed as
Identifiers
42458138What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.